Jade Biosciences Says Phase 3 Start Of JADE101 In IgA Nephropathy Accelerated To Q4 2026; Phase 2 Interim Data Expected In Q2 2027
Share
Why It Matters
Jade Biosciences moved up the start date for a big drug test to late 2026. When a company speeds up testing, it can mean they feel confident about the medicine.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.